Ascendis Pharma (ASND) Received its Third Buy in a Row

After Canaccord Genuity and J.P. Morgan gave Ascendis Pharma (NASDAQ: ASND) a Buy rating last month, the company received another Buy, this time from Stifel Nicolaus. Analyst Derek Archila reiterated a Buy rating on Ascendis Pharma today. The company’s shares closed last Friday at $130.25.

According to TipRanks.com, Archila is a 4-star analyst with an average return of 7.7% and a 45.1% success rate. Archila covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Phasebio Pharmaceuticals, and Madrigal Pharmaceuticals.

Currently, the analyst consensus on Ascendis Pharma is a Strong Buy with an average price target of $195.43, representing a 53.4% upside. In a report issued on June 1, Canaccord Genuity also maintained a Buy rating on the stock with a $196.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $183.98 and a one-year low of $119.11. Currently, Ascendis Pharma has an average volume of 223.3K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. Through its TransCon technology, it develops a pipeline of sustained release prodrug therapies including endocrinology product candidates to support the market. The company was founded by Jan Moller Mikkelsen and Harald Rau in September 2006 and is headquartered in Hellerup, Denmark.